AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 8, 2016
October 27 2016 - 7:00AM
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that it will report financial
results for the quarter ended September 30, 2016 after the market
closes on Tuesday, November 8, 2016. AGTC management will host a
conference call beginning at 5:00 pm Eastern Time that day to
review results and provide a corporate update.
To access the call, dial 866-565-7742 (US) or
614-999-1914 (outside of the US). The passcode is 4458790. A live
webcast will be available in the Events and Presentations section
of the Investor Relations page at http://ir.agtc.com/events.cfm.
Please log in approximately 10 minutes prior to the scheduled start
time.
The archived webcast will be available in the
Events and Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company
that uses its proprietary gene therapy platform to develop products
designed to transform the lives of patients with severe diseases,
with an initial focus in ophthalmology. AGTC's lead product
candidates are designed to treat inherited orphan diseases of the
eye, caused by mutations in single genes that significantly affect
visual function and currently lack effective medical
treatments.
AGTC's product pipeline includes six named
ophthalmology development programs across five targets (X-linked
retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP),
achromatopsia, wet age-related macular degeneration and blue cone
monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin
deficiency and adrenoleukodystrophy) and AGTC is continuing to
develop early research studies in additional indications. The
company is also exploring genetic defects in cells in the inner ear
that lead to deafness and expects to advance several product
candidates into development within the next few years. AGTC employs
a highly targeted approach to selecting and designing its product
candidates, choosing to develop therapies for indications having
high unmet medical need, clinical feasibility and commercial
potential. AGTC has a significant intellectual property portfolio
and extensive expertise in the design of gene therapy products
including capsids, promoters and expression cassettes, as well as,
expertise in the formulation, manufacture and physical delivery of
gene therapy products.
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com
Corporate Contact:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024